-
公开(公告)号：US09908886B2
公开(公告)日：2018-03-06
申请号：US14363718
申请日：2013-04-01
Applicant: Agency for Science, Technology and Research
IPC: C07D487/04 , A61K31/5025 , A61K31/519 , C07D235/06 , C07D471/04 , C07D519/00 , A61K45/06 , A61K31/4184 , A61K31/437 , A61K31/4985 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K31/553 , C07D471/10 , C07D491/107
CPC classification number: C07D487/04 , A61K31/4184 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K31/553 , A61K45/06 , A61P35/00 , C07D235/06 , C07D471/04 , C07D471/10 , C07D491/107 , C07D519/00 , A61K2300/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
-
公开(公告)号：US10280168B2
公开(公告)日：2019-05-07
申请号：US14517415
申请日：2014-10-17
Applicant: Agency for Science, Technology and Research
Inventor： Kassoum Nacro
IPC: C07D487/04 , C07D235/04 , C07D471/10 , C07D471/04 , A61K31/535
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazopyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.
-
公开(公告)号：US09884867B2
公开(公告)日：2018-02-06
申请号：US15026955
申请日：2014-10-03
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Kassoum Nacro , Lohitha Rao Chennamaneni
IPC: C07D487/04 , C07D471/04 , C07D519/00
CPC classification number: C07D487/04 , C07D471/04 , C07D519/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazopyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases.
-
4.发明申请BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF 有权作为MNK1和MNK2调节剂的双相杂环衍生物及其用途公开(公告)号：US20140371199A1
公开(公告)日：2014-12-18
申请号：US14363718
申请日：2013-04-01
Applicant: Agency for Science, Technology and Research
Inventor： Kassoum Nacro , Athisayamani Jeyaraj Duraiswamy , Lohitha Rao
IPC: C07D487/04 , A61K31/5377 , A61K31/551 , C07D491/107 , A61K31/5025 , A61K45/06 , C07D471/04 , A61K31/496 , A61K31/4545 , C07D471/10 , A61K31/437 , A61K31/4985 , A61K31/553
CPC classification number: C07D487/04 , A61K31/4184 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K31/553 , A61K45/06 , A61P35/00 , C07D235/06 , C07D471/04 , C07D471/10 , C07D491/107 , C07D519/00 , A61K2300/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
Abstract translation: 本发明涉及作为MAP激酶相互作用激酶MNK2a，MNK2b，MNK1a和MNK1b的抑制剂的某些化合物（例如咪唑并吡嗪，咪唑并吡啶，咪唑并嗪和咪唑嘧啶化合物）。 本发明还涉及包含这些化合物的药物组合物，以及该化合物在制备用于预防和治疗疾病（例如增殖性疾病（例如癌症），炎性疾病，阿尔茨海默氏病））的药物中的用途， 以及治疗这些疾病的方法。
-
公开(公告)号：US10544149B2
公开(公告)日：2020-01-28
申请号：US15858733
申请日：2017-12-29
Applicant: Agency for Science, Technology and Research
Inventor： Kassoum Nacro , Lohitha Rao Chennamaneni
IPC: C07D487/04 , C07D471/04 , C07D519/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases.
-
Patent Agency Ranking
公开(公告)号：US11040978B2
公开(公告)日：2021-06-22
申请号：US16432469
申请日：2019-06-05
Applicant: Agency for Science, Technology, and Research
IPC: C07D487/04 , C07D235/06 , C07D471/04 , C07D519/00 , A61K45/06 , A61K31/4184 , A61K31/437 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61P35/00 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K31/553 , C07D471/10 , C07D491/107
Abstract: The present invention relates to compounds of Formula (Ib-I) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
-
公开(公告)号：US20190315755A1
公开(公告)日：2019-10-17
申请号：US16432469
申请日：2019-06-05
Applicant: Agency for Science, Technology, and Research
IPC: C07D487/04 , A61P35/00 , A61K31/5025 , A61K31/5377 , A61K31/551 , A61K31/553 , C07D471/10 , A61K31/4545 , A61K31/496 , C07D519/00 , C07D471/04 , C07D235/06 , A61K31/4985 , A61K31/437 , A61K31/4184 , A61K45/06 , A61K31/519 , C07D491/107
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
-
公开(公告)号：US20190211020A1
公开(公告)日：2019-07-11
申请号：US16298959
申请日：2019-03-11
Inventor： Kassoum Nacro , Stephane Baudouin , Peter Scheiffele
IPC: C07D487/04 , C07D471/04 , C07D235/04 , C07D471/10
CPC classification number: C07D487/04 , C07D235/04 , C07D235/06 , C07D471/04 , C07D471/10
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.
-
公开(公告)号：US20180208600A1
公开(公告)日：2018-07-26
申请号：US15872571
申请日：2018-01-16
Applicant: Agency for Science, Technology and Research
IPC: C07D487/04 , A61K45/06 , A61K31/437 , A61K31/553 , C07D235/06 , A61K31/4545 , C07D519/00 , A61K31/519 , A61K31/5377 , A61K31/551 , C07D491/107 , A61K31/5025 , C07D471/10 , A61K31/496 , A61K31/4985 , A61K31/4184 , C07D471/04
CPC classification number: C07D487/04 , A61K31/4184 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K31/553 , A61K45/06 , A61P35/00 , C07D235/06 , C07D471/04 , C07D471/10 , C07D491/107 , C07D519/00 , A61K2300/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
-
公开(公告)号：US20180194771A1
公开(公告)日：2018-07-12
申请号：US15858733
申请日：2017-12-29
Applicant: Agency for Science, Technology and Research
Inventor： Kassoum Nacro , Lohitha Rao Chennamaneni
IPC: C07D487/04 , C07D471/04 , C07D519/00
Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.035 seconds)
